<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26786">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01966315</url>
  </required_header>
  <id_info>
    <org_study_id>B-1307/212-010</org_study_id>
    <nct_id>NCT01966315</nct_id>
  </id_info>
  <brief_title>The Comparison of Dexmedetomidine and Midazolam for the Sleep in Intensive Care Unit</brief_title>
  <official_title>The Comparison of Dexmedetomidine and Midazolam for the Sleep of Mechanical Ventilated Intensive Care Unit Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are going to compare the sleep quality and quantity between
      dexmedetomidine group and midazolam group using 24 hour polysomnography in critically ill
      patients. And the investigators also compare the incidence of delirium between the two
      groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sleep is very important for cognitive and immune function. However, patients in intensive
      care unit (ICU) have a very poor sleep.

      Almost all ventilated patients in intensive care unit (ICU) take a sedative drug. In Korea,
      most commonly used sedative drugs are dexmedetomidine and midazolam.

      The investigators are going to compare the sleep quality and quantity between
      dexmedetomidine group and midazolam group using 24 hour polysomnography. And the
      investigators also compare the incidence of delirium between the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The differences of sleep stage, sleep efficiency, arousal index and delirium between dexmedetomidine group and midazolam group</measure>
    <time_frame>during ICU stay</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Poor Quality Sleep</condition>
  <condition>Sleep Deprivation</condition>
  <condition>Sleep Arousal Disorders</condition>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <description>Dexmedetomidine group is the patients who sedated with dexmedetomidine in intensive care unit. We will randomly allocate using www.randomizer.org.
They will sedate at the level of RASS -2. The dose of dexmedetomidine will be 0.2-0.7ug/kg/hr.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam group</arm_group_label>
    <description>Midazolam group is the patients who sedated with midazolam in intensive care unit. We will randomly allocate using www.randomizer.org.
They will sedate at the level of RASS -2. The dose of midazolam will be 0.05-0.1 mg/kg/hr.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Critical patients who take a sedative drugs (dexmedetomidine or midazolam).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  sedation patients with dexmedetomidine or midazolam

          -  over 18 years old

        Exclusion Criteria:

          -  Neurologic disease (stroke, seizure, dementia, hypoxic brain damage)

          -  Brain infection

          -  Alcoholics

          -  Major Depression Disorder, Schizophrenia, Anxiety disorder

          -  Hearing loss
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Jae Cho, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi, Republic of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Jae Cho, MPH</last_name>
    <phone>+82-10-9928-1081</phone>
    <email>lungdrcho@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Se Joong Kim, PhD</last_name>
    <phone>+82-10-8862-1146</phone>
    <email>ksj1146@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Jae Cho, MPH</last_name>
      <phone>+82-10-9925-7058</phone>
      <email>lungdrcho@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Se Joong Kim, PhD</last_name>
      <phone>+82-10-8862-1146</phone>
      <email>ksj1146@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>Young-Jae Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>October 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Sleep Deprivation</mesh_term>
    <mesh_term>Sleep Arousal Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
